Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics for cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension (PAH). The company’s lead product candidate is IKT-001, an oral prodrug of imatinib mesylate designed to improve tolerability and adherence while targeting aberrant signaling through type III receptor tyrosine kinases. Inhibikase holds global commercialization rights to IKT-001 and is currently conducting the IMPROVE-PAH Phase 3 clinical study to evaluate the drug’s efficacy and safety in patients with PAH. The company has established bioequivalence between IKT-001 and imatinib and is pursuing Orphan Drug Designation for the PAH indication. Its development strategy leverages the established safety profile of imatinib, which has been used in oncology since 2001, to address the progressive nature of PAH.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage inhibikase.com
Sector Healthcare IR page inhibikase.com/investors
Tags
pulmonary arterial hypertension, cardiopulmonary diseases, prodrug, tyrosine kinase inhibitors, orphan drugs, clinical-stage, imatinib, rare diseases, IKT-001, IMPROVE-PAH, imatinib mesylate, CorHepta Pharmaceuticals
Press page inhibikase.com/investors/news-events/press-releases

Metrics

Valuation  
Market cap $ 288.254M
Market cap (USD) $ 288.254M
P/E -5.01
PEG —
P/BV 1.53
P/S —
P/OCF -5.84
P/FCF -5.84
Dividend yield —
Turnover / mcap —
Returns  
ROE -36.0%
ROI -27.9%
ROIC -22.5%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -71.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue — 0 260.501K 123.44K 3.101M 0
Net profit -48.259M -27.52M -19.029M -18.054M -14.786M 0
Free cash flow -27.8M -19.148M -18.099M -17.594M -14.297M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 2.05 3.25 1.27 0.5 1.47 —
Price performance 12m -0.37 1.56 1.54 -0.66 -0.79 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 0.00 145,836 150,095 110,517 0.00
Lease liabilities (USD) — — — 351,287 240,219 110,517 —
Cash and deposits (USD) 18,457 14M 40.8M 7.19M 9.17M 56.5M 179M
Right-of-use assets (USD) — — 0.00 328,643 222,227 101,437 0.00
Net debt (borrowings + leases - cash) (USD) — — -40.8M -6.69M -8.78M -56.3M -179M
Cash flow detail
Operating cash flow (USD) — -1.13M -14.3M -17.4M -18.1M -19.1M -27.8M
Purchases of property, plant and equipment (USD) — — 0.00 -243,255 -14,238 0.00 -13,399
Change in receivables (cash effect) (USD) — 0.00 -110,141 70,258 39,881 0.00 —
Change in payables (cash effect) (USD) — -247,071 -630,902 61,395 -504,406 271,782 146,827
Interest paid (cash effect) (USD) — -6,249 -1,148 -973 0.00 — —
Share-based compensation (USD) — 573,695 1.53M 458,147 500,148 8.14M 15.3M
Operating cash flow before change in receivables (USD) — -1.13M -14.2M -17.4M -18.1M -19.1M —
Free cash flow (OCF - PPE - intangibles) (USD) — — -14.3M -17.6M -18.1M -19.1M -27.8M
Income detail
Research and development expense (USD) — 893,802 11.4M 12M 13.6M 17.2M 29.8M
↳ 5y CAGR +101.6%
Reported May 17, 2021 Mar 31, 2022 Mar 31, 2023 Mar 31, 2023 Mar 27, 2024 Mar 27, 2025 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Inhibikase Therapeutics Announces Third Quarter 2026 Bull 2 Bear 4 Results

Financial Results and Highlights Recent Activity

WILMINGTON, Del., November 10, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2026, and highlighted recent developments.

“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We continue to expand our clinical footprint and look forward to additional country and site activations over the coming months.

October 27, 2026 8:00am EDT Download as PDF

WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced that the Company’s management will be participating in the following investor conferences during the month of November and December 2026.

Jefferies Global Healthcare Conference
November 16–19, 2026
London, United Kingdom
Presentation Details: Fireside Chat with Mark Iwicki, CEO of Inhibikase and Dennis Ding, Jefferies Research on Monday, November 16 at 3:00pm (GMT)
Meeting Details: one-on-one meetings on Monday, November 16 and Tuesday, November 17
Webcast: Click here

Investors interested in scheduling a meeting should contact their Jefferies representative.

**9th Annual Evercore Healthcare Conference
**November 30–December 2, 2026
Coral Gables, Florida
Meeting Details: one-on-one meetings on Tuesday, December 1

Investors interested in scheduling a meeting should contact their Evercore representative.

About Inhibikase (www.inhibikase.com)

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential of IKT-001, the advancement of the IMPROVE-PAH study, and the anticipated contribution of Dr. Wasserman to the Company's board of directors. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

October 20, 2026 4:01pm EDT Download as PDF

WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s appointment, the Company also announced the resignation of Dennis Berman from the Company’s Board.

“We thank Dennis for his many contributions to the Company during his years of service,” said Amit Munshi, Chair of the Inhibikase Board of Directors.

Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a cardiologist with more than two decades of experience in clinical development and company leadership. At Amgen Inc., he served as Vice President, Global Development and Therapeutic Area Head for Bone, Cardiovascular, Metabolic and Neuroscience. He was Amgen’s first cardiologist and built the company’s cardiovascular and metabolic strategy, team and portfolio. He led the global development and approvals of Repatha (evolocumab), was instrumental in the development and U.S. FDA approval of Evenity (romosozumab) and oversaw the U.S. approval of Aimovig (erenumab).

“Scott has taken multiple programs from early development through global approval, and he has built clinical organizations at both large and emerging companies,” said Amit Munshi. “We look forward to benefiting from his expertise as we continue to advance our global Phase 3 IMPROVE-PAH study of IKT-001. We are pleased to welcome Scott to our Board.

“PAH is a progressive, life-threatening disease, and the pedigree of imatinib together with the recent preclinical and Phase 1 data for IKT-001 point to a very promising role for this asset in this difficult to treat condition,” said Dr. Wasserman. “This is an important time for Inhibikase, and I look forward to applying my experience in global clinical development and regulatory interactions as the Company advances IMPROVE-PAH.”

Scott brings deep expertise in clinical development to Inhibikase’s Board of Directors, spanning global development strategy, clinical trial design and execution, and global regulatory interactions. Most recently, Scott served as Venture Partner at Frazier Life Sciences, focusing on company creation. Prior to Frazier, Scott was the CEO and co-founder of Latigo Biotherapeutics, a venture-backed biotechnology company developing first and best-in-class, non-opioid pain medicines. Prior to his role with Latigo, Scott was Vice President, Global Development Therapeutic Area Head for Bone, Cardiovascular, Metabolic, and Neuroscience at Amgen. In addition to his role in the development of Repatha, Evenity, and Aimovig, Scott oversaw therapeutic development for a range of other conditions, including heart failure, anemia, obesity, and Alzheimer’s disease.

Prior to joining industry, Scott was on faculty at Stanford University in the Division of Cardiovascular Medicine conducting NIH-sponsored research on endothelial gene expression and served as a non-interventional cardiologist at the Veterans Administration Hospital in Palo Alto, CA. Scott received his BS, Magna Cum Laude from Haverford College and his MD, Magna Cum Laude from Harvard Medical School. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University and post-doctoral cardiovascular research at COR Therapeutics, Millennium Pharmaceuticals, and Stanford.

About Inhibikase (www.inhibikase.com ) 

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential of IKT-001, the advancement of the IMPROVE-PAH study, and the anticipated contribution of Dr. Wasserman to the Company's board of directors. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Prompts

Inhibikase Therapeutics, Inc. (ticker IKT), listed in United States.

ETFs Holding Inhibikase Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 136,701 $ 198.216K Nov 16, 2026
DFSU 0.00% 4,320 $ 6,609.60 Nov 12, 2026
DXUV 0.00% 5,822 $ 8,907.66 Nov 12, 2026